RxDoctor Payments Data

Takeshia Niday, MD

Psychiatry · San Diego, CANPI 1932429289

Payments from drug & device makers

$9,615in general payments, 2019–2025

Across 313 payments — averaging $30.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$2K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Otsuka America Pharmaceutical, Inc.$1K
  • Neurocrine Biosciences, Inc.$942
  • Johnson & Johnson$664
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$547
  • plus $3K from 16 others

What the payments were for

  • Food & beverage$9,50599%
  • Education$1091%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,615 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$290,976
Medicare patients
382
Services billed
3,274

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate95$666,784
Austedo XrDeutetrabenazine30$183,317
Invega SustennaPaliperidone Palmitate20$70,314
AristadaAripiprazole Lauroxil21$61,713
FanaptIloperidone26$23,194
RexultiBrexpiprazole18$13,106
Chlorpromazine Hcl15$4,274
Quetiapine Fumarate88$3,040
Divalproex Sodium63$2,511
Lurasidone Hcl44$2,108
Risperidone89$1,583
Olanzapine73$1,413
Paliperidone ErPaliperidone13$1,348
Trazodone Hcl74$1,327
Buspirone Hcl36$1,308

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$942$666,78495 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$1,362$183,31730 claims
Johnson & JohnsonInvega Sustenna$664$70,31420 claims
Alkermes, Inc.Aristada$2,436$61,71321 claims
Vanda Pharmaceuticals Inc.Fanapt$215$23,19426 claims
Otsuka America Pharmaceutical, Inc.Rexulti$1,153$13,10618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.

Other psychiatry in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →